D. E. Shaw & Co. Inc. Buys 113,191 Shares of MiMedx Group, Inc. (NASDAQ:MDXG)

D. E. Shaw & Co. Inc. boosted its holdings in MiMedx Group, Inc. (NASDAQ:MDXG - Free Report) by 87.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 242,942 shares of the company's stock after purchasing an additional 113,191 shares during the quarter. D. E. Shaw & Co. Inc. owned about 0.17% of MiMedx Group worth $2,337,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in MDXG. IMG Wealth Management Inc. acquired a new stake in shares of MiMedx Group during the 4th quarter worth approximately $28,000. Van ECK Associates Corp bought a new position in MiMedx Group during the fourth quarter worth $40,000. Tower Research Capital LLC TRC boosted its stake in MiMedx Group by 77.4% during the fourth quarter. Tower Research Capital LLC TRC now owns 6,501 shares of the company's stock worth $63,000 after acquiring an additional 2,837 shares in the last quarter. AlphaQuest LLC acquired a new stake in MiMedx Group in the fourth quarter worth $88,000. Finally, Savant Capital LLC bought a new stake in MiMedx Group in the fourth quarter valued at $100,000. 79.15% of the stock is currently owned by institutional investors.

Insider Activity at MiMedx Group

In other MiMedx Group news, CAO William Frank Iv Hulse sold 54,596 shares of the company's stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $7.89, for a total value of $430,762.44. Following the completion of the sale, the chief accounting officer now directly owns 440,178 shares of the company's stock, valued at approximately $3,473,004.42. This represents a 11.03% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Kimberly Maersk-Moller sold 4,106 shares of the business's stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $7.89, for a total value of $32,396.34. Following the completion of the transaction, the insider now owns 310,836 shares in the company, valued at $2,452,496.04. The trade was a 1.30% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 144,018 shares of company stock valued at $1,130,312. 1.70% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on MDXG. Wall Street Zen cut shares of MiMedx Group from a "strong-buy" rating to a "buy" rating in a research report on Friday, May 9th. Cantor Fitzgerald reissued an "overweight" rating and issued a $13.00 price objective on shares of MiMedx Group in a research note on Thursday, February 27th.

MiMedx Group Stock Down 1.3%

Shares of NASDAQ:MDXG traded down $0.09 during midday trading on Monday, hitting $6.63. 383,770 shares of the company's stock were exchanged, compared to its average volume of 693,547. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.10 and a quick ratio of 3.53. MiMedx Group, Inc. has a 12 month low of $5.47 and a 12 month high of $10.14. The company has a market cap of $979.26 million, a PE ratio of 12.05 and a beta of 1.85. The stock has a 50 day moving average price of $7.06 and a 200-day moving average price of $8.17.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last posted its earnings results on Wednesday, April 30th. The company reported $0.06 earnings per share for the quarter, meeting analysts' consensus estimates of $0.06. The company had revenue of $88.21 million for the quarter, compared to analyst estimates of $86.32 million. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%. On average, sell-side analysts anticipate that MiMedx Group, Inc. will post 0.3 EPS for the current fiscal year.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.